ClinicalTrials.gg
Not yet recruitingNCT07832708Updated Sep 22, 2026

Study to Assess Adverse Events and How Oral ABBV-1162 Moves Through the Body of Healthy Adults

A Phase 1 interventional study of ABBV-1162 and Placebo in Healthy Volunteers, sponsored by AbbVie. Not yet recruiting. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-22.

Sponsored by AbbVie · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

The goal of this study is to evaluate the safety, tolerability, and pharmacokinetics of ABBV-1162 in healthy adults.

02

Conditions studied

  • Healthy Volunteers

Keywords

  • Healthy Volunteers, ABBV-1162
03

In context

Lead sponsor

AbbVie is the lead sponsor of 977 studies on the registry; 135 are open to participants now.

Of its 359 completed or terminated interventional studies of FDA-regulated products, 215 (60%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Inclusion Criteria:

  • Healthy individuals in general good health.
  • Blood pressure and heart rate measurements within specified ranges: systolic blood pressure \< 140 mmHg, diastolic blood pressure \< 90 mmHg, heart rate \<= 100 bpm and >= 55 bpm, absence of orthostatic hypotension.
05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
40 participants (estimated)

Study arms

  • Experimental
    ABBV-1162

    Participants will receive a single oral dose of ABBV-1162.

    Drug: ABBV-1162

  • Placebo comparator
    Placebo

    Participants will receive a single oral dose of placebo.

    Drug: Placebo

Interventions

  • DrugABBV-1162

    Oral

  • DrugPlacebo

    Oral

06

What researchers measure

Primary outcomes

  1. Number of Participants Experiencing Adverse Events

    An AE is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment.

    Time frame: Up to approximately 31 days

  2. Maximum Plasma Concentration (Cmax) of ABBV-1162

    Cmax of ABBV-1162

    Time frame: Up to approximately 3 days

  3. Time to Cmax (Tmax) of ABBV-1162

    Time to Cmax (Tmax) of ABBV-1162

    Time frame: Up to approximately 3 days

  4. Terminal Phase Elimination Rate Constant (Beta) of ABBV-1162

    Beta of ABBV-1162

    Time frame: Up to approximately 3 days

  5. Terminal Phase Elimination Half-Life (t1/2) of ABBV-1162

    t1/2 of ABBV-1162

    Time frame: Up to approximately 3 days

  6. Area Under the Plasma Concentration-Time Curve (AUC) From Time 0 to the Time of the Last Measurable Concentration (AUCt) of ABBV-1162

    AUCt of ABBV-1162

    Time frame: Up to approximately 3 days

  7. AUC From Time 0 to the Time Infinity (AUCinf) of ABBV-1162

    AUCinf of ABBV-1162

    Time frame: Up to approximately 3 days

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Nov 2026; primary completion for May 2027, 6 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 16, 2026
First posted
Sep 22, 2026
StartEst.
Nov 2, 2026
Primary completionEst.
May 2027
CompletionEst.
May 2027
Last update
Sep 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 22, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07832708
Lead sponsor
AbbVie
Responsible party
Sponsor
First posted
Sep 22, 2026
Start date
Nov 2, 2026 (estimated)
Primary completion
May 2027 (estimated)
Completion
May 2027 (estimated)
Last update
Sep 22, 2026

Study contacts

ABBVIE CALL CENTER
Contact
abbvieclinicaltrials@abbvie.com
844-663-3742
ABBVIE INC.
study director · AbbVie

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion